Ipsen S.A. Aktie

Ipsen S.A. is an international biopharmaceutical enterprise, founded in 1929 and based in Boulogne-Billancourt, France. The company is dedicated to discovering, developing, and marketing innovative medicines globally, focusing on several key therapeutic areas: oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. Its extensive product lineup includes Somatuline, prescribed for neuroendocrine tumors and acromegaly; Decapeptyl, an agent for advanced metastatic prostate cancer; Cabometyx, addressing renal cell carcinoma and second-line hepatocellular carcinoma; and Onivyde, indicated for second-line metastatic pancreatic cancer. For neurological and aesthetic applications, Ipsen offers Dysport, used for motor muscular disorders and cosmetic purposes. The company also provides treatments for growth-related conditions, such as NutropinAq for growth failure in children (due to growth hormone deficiency, Turner syndrome, or chronic renal failure) and adults with growth hormone deficiency, along with Increlex for growth failure in pediatric and adolescent patients. In the realm of digestive health, Ipsen's offerings feature Smecta for both chronic and acute diarrhea, as well as pain associated with functional bowel diseases; Forlax for constipation; and Fortrans/Eziclen for bowel preparation before endoscopy, X-ray examinations, and colonic surgery. Other specialized products include Xermelo for carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device for symptomatic relief of gas-related gastrointestinal discomfort; and Etiasa for inflammatory bowel diseases. Furthermore, Tanakan is available for treating cognitive disorders in adults, vestibular vertigo, vestibular rehabilitation, and tinnitus. Ipsen's consumer healthcare division also markets various over-the-counter gastrointestinal remedies, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. To expand its research and market reach, Ipsen S.A. engages in strategic collaborations and alliances with numerous partners, such as Debiopharm, Exelixis, Galderma, Blueprint Medicines, TerSera Therapeutics, Rhythm Pharmaceuticals, Teijin, Braintree Laboratories, Ethypharm, Schwabe, BAKX Therapeutics Inc., and Exicure.